|Series A, 6/04 |
|Series B, 10/06 ||$7.5M|
|Venture Round, 8/08 ||$5M|
|Series C, 11/08 |
Inventages Venture Capital Investment Inc.
|Series D, 1/11 ||$11M|
Accera, Inc., a biotechnology company, engages in the discovery and development of therapeutic drugs for neurodegenerative diseases. It offers Ketasyn, a molecule for Alzheimer’s, Parkinson’s, and age associated memory impairment.
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimerâ€™s. Dispensed by prescription, it targets the metabolic deficiencies and imbalances associated with AD by providing an alternative energy source for brain cells.